BioXcel Therapeutics Inc To Discuss The Data Results From The Phase 2 Trial of BXCL701 Call Transcript
Good morning, and welcome to the BioXcel Therapeutics conference call to review the positive overall survival results from the company's Phase II trial of BXCL701 for patients with small cell neuroendocrine prostate cancer. (Operator Instructions)
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarterly period ended June 30, 2023, which can be found at www.bioxceltherapeutics.com or on www.sec.gov. As a reminder, today's conference call and webcast are being recorded.
Joining us are Dr. Vimal Mehta,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |